Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXA-NK02
- Development stage
- Phase 1
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AXA-NK02 is an allogeneic, "off-the-shelf" natural killer (NK) cell therapy derived from human embryonic stem cells (hESCs). Developed by researchers at the Shanghai Jiao Tong University School of Medicine, it is currently being investigated in early-phase clinical trials for the treatment of refractory lupus nephritis and systemic lupus erythematosus. The therapy leverages the innate cytotoxic and immunomodulatory properties of NK cells to potentially reset the autoimmune response and reduce renal inflammation in patients who have failed standard treatments. By utilizing hESCs as a starting material, AXA-NK02 aims to provide a standardized, scalable, and readily available therapeutic product, overcoming the logistical and variability challenges associated with autologous or primary donor-derived cell therapies.
- Other names
- ES-NK Cell InjectionhESC-derived NK cells
Beyond the preview
Go deeper on AXA-NK02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXA-NK02.